ARS Pharmaceuticals develops neffy, the first FDA-approved needle-free epinephrine nasal spray, providing a portable and easy-to-use alternative for individuals at risk of severe allergic reactions. This product addresses the challenges of needle-related risks and the anxiety associated with traditional epinephrine delivery methods.
Funding
$55M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many individuals at risk of severe allergic reactions face challenges with traditional epinephrine auto-injectors, including needle-related anxiety, portability issues, and ease of use, potentially delaying or hindering timely treatment.
Solution
ARS Pharmaceuticals offers neffy (epinephrine nasal spray), the first FDA-approved needle-free epinephrine nasal spray, providing a more convenient and less intimidating alternative for individuals at risk of anaphylaxis. This nasal spray eliminates the need for needles, addressing concerns about needle phobia and accidental needle sticks, while offering a compact and readily accessible delivery method. The product aims to empower patients and caregivers to administer epinephrine quickly and effectively, potentially improving response times during allergic emergencies. By providing a user-friendly option, ARS Pharmaceuticals seeks to improve adherence to epinephrine prescriptions and enhance the overall management of severe allergies.
Target Audience
The primary target audience includes individuals with diagnosed allergies at risk of anaphylaxis, their caregivers, and healthcare providers seeking alternative epinephrine delivery methods.
Features
- Needle-free nasal spray formulation for epinephrine delivery
- Portable and easy-to-use design for convenient administration
- FDA-approved for the treatment of severe allergic reactions (anaphylaxis)
- Eliminates needle-related anxiety and risk of accidental needle sticks